Sponsor pipeline

Travere Therapeutics, Inc. clinical trial pipeline

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT07219121	Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental…	Proteinuria	Active, Not Recruiting	2026-06-23
Phase 3
NCT06247085	Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU)…	Homocystinuria	Recruiting	2026-10-08
NCT06431893	A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase…	Homocystinuria	Enrolling by Invitation	2026-05-28
Phase 2
NCT05003986	Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases	Focal Segmental Glomerulosclerosis	Recruiting	2026-05-12
Phase 1/2
NCT03406611	Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…	Homocystinuria	Recruiting	2026-08-10

Get alerts when Travere Therapeutics, Inc.'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.